Shots:

• AbbVie and Harvard University enter a $30M research alliance to study & develop novel therapies against emergent viral infections with an initial focus on coronavirus and the viruses leading to hemorrhagic fever
• The focus of the collaboration is to integrate fundamental biology into the pre/clinical development of new therapies for viral diseases
• AbbVie will deploy expertise and facilities to advance collaborative research and early-stage development efforts across five program addressing multiple therapeutic modalities: immunity and immunopathology- host targeting for antiviral therapies- antibody therapeutics- small molecules- and translational development

­ Ref: AbbVie | Image: abbvie